Bayerische Julius-maximilians-universitat Wurzburg

Julius-maximilians-universtitat-wurzburg

Julius-maximilians-universitat Wurzburg

Julius-maximilians-universitaet Wuerzburg

Viacheslav Nikolaev

Martin Lohse

Roland Jahns

Valérie Jahns

Moritz Bünemann

Valerie Jahns

Martin J Lohse

Moritz Bunemann

The present invention relates to novel &#x3b2;-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid molecules encoding these cyclopeptide-mutants and linear peptides. Moreover, vectors and recombinant host cells comprising said nucleic acid molecule and a method for producing the disclosed cyclopeptide-mutants are provided. Further provided is a composition comprising the peptides, nucleic acid molecules, vectors or host cells of the invention. The present invention also relates to therapeutic and diagnostic means, methods and uses taking advantage of the peptides of the invention and to means, methods and uses for detecting anti-&#x3b2;-adrenergic receptor antibodies like anti-&#x3b2;-adrenergic receptor antibodies.

[object Object]

Described is a chimeric peptide, comprising, in order, (a) a first detectable label (b) a cAMP binding moiety having only one cAMP binding site and (c) a second detectable label least two detectable labels is describe. The chimeric peptide is useful for direct determination of cAMP concentration in vitro and/or in vivo. Also described are nucleic acids encoding the chimeric peptide, methods of making and modifying the chimeric peptide, a method for determining the cAMP concentration, and kits.

Means and methods for the determination of camp in vitro and in vivo

Growing community of inventors

Würzburg, Germany

Viacheslav Nikolaev